TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23698253
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of temsirolimus and pazopanib
Study: 23700789
Drug: L-NAME 0
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME 0 mg.kg-1 (Control)
Study: 23700789
Drug: L-NAME 1
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME 1 mg.kg-1
Study: 23700789
Drug: L-NAME 2
Normalized name: β-L-2'-deoxythymidine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: L-NAME 2 mg.kg-1
Study: 23700789
Drug: L-NAME 4
Normalized name: 4-hydroxy-L-phenylalanine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-NAME 4 mg.kg-1
Study: 23701810
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment (antidepressants, anticonvulsants, opiates)
Study: 23701810
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with 5% lidocaine medicated plaster
Study: 23701891
Drug: Integrative cognitive-affective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative cognitive-affective therapy (ICAT)
Study: 23701891
Drug: Enhanced cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced cognitive-behavioral therapy (CBT-E)
Study: 23703723
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss intervention (exercise, behavior, and nutrition therapy)
Study: 23706985
Drug: Nab-paclitaxel at
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel at 260 mg/m(2) intravenously every 3 weeks.
Study: 23707169
Drug: F4/AS01 candidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: F4/AS01 candidate vaccine
Study: 23710653
Drug: IV anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV anidulafungin followed by oral voriconazole
Study: 23710698
Drug: Vaginal dilators,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal dilators, topical corticosteroids, and estrogen for vaginal cGVHD.
Study: 23715103
Drug: Regular plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular plasma treatment for hereditary TTP
Study: 23715577
Drug: Dasatinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (60 to 120 mg/m(2) once daily)
Study: 23716538
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg/day orally on days 1 - 21 (28-day cycle); melphalan 0.18 mg/kg orally on days 1-4; dexamethasone 40 mg orally on days 1, 8, 15, and 22
Study: 23716541
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m(2))
Study: 23719348
Drug: Efavirenz, didanosine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz, didanosine, and lamivudine (combined therapy)
Study: 23719651
Drug: Uniblocker® inserted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniblocker® inserted into the endotracheal tube and advanced until the blocker balloon just protruded from the endotracheal tube tip
Study: 23719719
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1.8 mg/kg by intravenous infusion every 3 weeks for up to 16 cycles)
Study: 23720019
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment with full-dose gemcitabine (1 g/m(2) over 30 minutes on days 1, 8, and 15) and oxaliplatin (85 mg/m(2) on days 1 and 15) with radiation therapy (30 Gray in 2-Gy fractions during cycle 1)
Study: 23720019
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment with full-dose gemcitabine, oxaliplatin, and RT
Study: 23720182
Drug: Monotherapy for
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy for PAH
Study: 23720182
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy for PAH
Study: 23720182
Drug: No PAH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No PAH drugs
Study: 23722308
Drug: Immunocryosurgery (liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunocryosurgery (liquid nitrogen, open spray, 2 × 15 s; day 14) during 5 weeks' imiquimod
Study: 23724846
Drug: Lambrolizumab (anti-PD-1)
Normalized name: Dianeal PD-2/1.5
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lambrolizumab (anti-PD-1) administered intravenously at a dose of 10 mg/kg every 2 or 3 weeks or 2 mg/kg every 3 weeks
Study: 23724846
Drug: Lambrolizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lambrolizumab (10 mg/kg every 2 weeks)
Study: 23724867
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (concurrent regimen)
Study: 23725004
Drug: AllerT (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: AllerT (combination of three COPs selected for undetectable IgE binding)
Study: 23726000
Drug: 3D-CRT (38.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D-CRT (38.5 Gy in 10 fractions twice daily over 5 days)
Study: 23726267
Drug: Tivozanib 0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib 0.5, 1.0 or 1.5mg/d orally (3 weeks on/1 week off) and temsirolimus 15 or 25 mg/week intravenously
Study: 23726971
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m(2) + cisplatin 75 mg/m(2) + cetuximab 250 mg/m(2) (loading dose: 400 mg/m(2))
Study: 23726971
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Platinum/5-fluorouracil plus cetuximab)
Study: 23729989
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of presenting anxiety disorder
Study: 23731330
Drug: Maraviroc plus
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc plus optimized background therapy (OBT)
Study: 23731760
Drug: MSCs treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSCs treatment
Study: 23731760
Drug: Immunological analysis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunological analysis post-MSC treatment
Study: 23731832
Drug: Lenalidomide 25mg
Normalized name: LENALIDOMIDE 25MG CAP,ORAL
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 25mg once daily on days 1-21 of each 28-day cycle for a maximum of 24 months
Study: 23732043
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (PI and NNRTI)
Study: 23733041
Drug: Two-dose rotavirus
Normalized name: ROTAVIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose rotavirus (RV) vaccine (RIX4414; GlaxoSmithKline Vaccines)
Study: 23733198
Drug: Non-ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ACE inhibitors
Study: 23733473
Drug: PaMZ (PA-824-moxifloxacin-pyrazinamide)
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PaMZ (PA-824-moxifloxacin-pyrazinamide) given at human-equivalent doses 5 days/week for 8 weeks
Study: 23733473
Drug: Both combination
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both combination regimens (PaMZ and RHZ)
Study: 23733802
Drug: No mTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mTOR inhibitor treatment (Control)
Study: 23733925
Drug: (99m)Tc-labeled PSMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: (99m)Tc-labeled PSMA inhibitors
Study: 23735702
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) at a dose of 40 mg/m² every 28 days for six courses
Study: 23737404
Drug: Lacosamide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (100 mg single oral dose)
Study: 23738760
Drug: Pre-transplant infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-transplant infusion of autologous MSC
Study: 23738760
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy without basiliximab
Study: 23739218
Drug: Fasting glucose
Normalized name: FAST TAKE (GLUCOSE) METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting glucose >7.0 mmol/l
Study: 23739218
Drug: Fasting glucose
Normalized name: FAST TAKE (GLUCOSE) METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting glucose between 6.1 and 7.0 mmol/l
Study: 23739218
Drug: Fasting glucose
Normalized name: FAST TAKE (GLUCOSE) METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting glucose <6.1 mmol/l
Study: 23740728
Drug: Enzyme immunoassay
Normalized name: snake venom detection kit, enzyme immunoassay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme immunoassay kit detecting serum IgA antibody to glycopeptidolipid core antigen from MAC
Study: 23743475
Drug: New generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: New generation of HCV-specific antiviral drugs
Study: 23744583
Drug: Cranial radiation
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial radiation therapy (CRT)
Study: 23746966
Drug: MSC1992371A (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC1992371A (oral aurora kinase inhibitor) at maximum tolerated doses of 37 mg/m(2)/day (days 1-3 and 8-10)
Study: 23746966
Drug: MSC1992371A (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC1992371A (oral aurora kinase inhibitor) at maximum tolerated doses of 28 mg/m(2)/day (days 1-6)
Study: 23750331
Drug: Rifampicin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (600 mg) with THC/CBD spray (10.8/10 mg)
Study: 23750331
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg) with THC/CBD spray (10.8/10 mg)
Study: 23750331
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg) with THC/CBD spray (10.8/10 mg)
Study: 23751980
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) - aspirin plus an NAAA
Study: 23751980
Drug: Nonaspirin antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonaspirin antiplatelet agents (NAAAs)
Study: 23751980
Drug: Nonusers (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonusers (no antiplatelet drugs)
Study: 23753030
Drug: Rituximab infusions
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab infusions and intensive chemotherapy (high-dose methotrexate, fractionated ifosfamide/cyclophosphamide, other drugs in rotation, intrathecal chemoprophylaxis)
Study: 23753030
Drug: Rituximab infusions
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab infusions and intensive chemotherapy
Study: 23753102
Drug: Cardiorespiratory fitness
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiorespiratory fitness (maximum oxygen uptake, mL/kg/min) measured with a maximal cycle ergometer test
Study: 23753102
Drug: Cardiorespiratory fitness
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiorespiratory fitness (maximum oxygen uptake, mL/kg/min)
Study: 23754575
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1.2 or 1.8 mg/kg intravenously)
Study: 23754575
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1.2 or 1.8 mg/kg intravenously) with rifampin (CYP3A inducer)
Study: 23754575
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1.2 or 1.8 mg/kg intravenously) with ketoconazole (CYP3A inhibitor)
Study: 23756764
Drug: Lenalidomide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (10 mg, 20 mg, 25 mg) and Sorafenib (200 mg, 400 mg) given orally once daily for 28 days (1 cycle).
Study: 23756764
Drug: Lenalidomide and
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide and Sorafenib treatment.
Study: 23759033
Drug: Treatment-seeking overweight
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-seeking overweight youth (parent-reported HRQoL)
Study: 23759033
Drug: Treatment-seeking overweight
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-seeking overweight youth (self-reported HRQoL)
Study: 23759033
Drug: Treatment-seeking status
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-seeking status
Study: 23760766
Drug: 3-week inpatient
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week inpatient program combining rehabilitative treatment and preventive, psychosocial, child-centered interventions
Study: 23761092
Drug: Continuous intraoperative
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intraoperative optical coherence tomography (OCT) measurements of anterior lens capsule position after removing the crystalline lens and after implanting a capsular tension ring (CTR).
Study: 23761422
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (r-hGH) therapy
Study: 23762229
Drug: Trivalent flu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent flu vaccine (AdimFlu-S®) 15 mcg of hemagglutinin for each strain/0.5 mL
Study: 23763917
Drug: Barasertib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barasertib (800 mg, 1000 mg, 1200 mg) plus low-dose cytosine arabinoside (LDAC) 20 mg (subcutaneous injection twice daily for 10 days) administered in 28-day cycles.
Study: 23765437
Drug: VKA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VKA therapy
Study: 23765437
Drug: Female gender/treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Female gender/treatment with gpIIb/IIIa-antagonists
Study: 23768574
Drug: Sublingual allergen
Normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual allergen immunotherapy (specific dosage and duration not available)
Study: 23769498
Drug: Target fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target fortified breast milk (fat: 4.4 g, protein: 3 g, carbohydrates: 8.8 g per 100 mL)
Study: 23770158
Drug: Enzastaurin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin (250 mg oral, 125 mg tablets twice a day; a 1125-mg loading dose on day 1)
Study: 23770972
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day aspirin plus 40 mg/day atorvastatin
Study: 23773637
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (monthly pulse-cyclophosphamide + azathioprine + prednisolone)
Study: 23774433
Drug: Telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 600 mg (adolescents)
Study: 23774433
Drug: Telbivudine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 15 mg/kg (children aged 2 to 12 years)
Study: 23774433
Drug: Telbivudine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 15 mg/kg (children 2 to 12 years)
Study: 23775962
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg once per day or 400 mg twice per day if no initial response
Study: 23777764
Drug: MDASI-CML administered
Normalized name: Mvasi
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MDASI-CML administered to patients every 2 weeks for 1 year
Study: 31665349
Drug: Arginine administration
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine administration
Study: 23782005
Drug: ATV/RTV 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV/RTV 300/100 mg once daily with zidovudine/lamivudine 300/150 mg twice daily
Study: 23782005
Drug: ATV/RTV 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV/RTV 400/100 mg once daily with zidovudine/lamivudine 300/150 mg twice daily
Study: 23782005
Drug: ATV/RTV treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV/RTV treatment
Study: 23782005
Drug: ATV/RTV treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV/RTV treatment of mothers
Study: 24332241
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg
Study: 29080970
Drug: Ibrutinib 840
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib 840 mg
Study: 23782157
Drug: Ibrutinib, 560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib, 560 mg daily
Study: 23782511
Drug: BM-MSCs therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BM-MSCs therapy (5 × 10(7) cells injected twice through the hepatic artery at weeks 4 and 8)
Study: 23782511
Drug: BM-MSCs therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BM-MSCs therapy
Study: 23782682
Drug: Haploidentical peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haploidentical peripheral blood stem cell infusions (1-2x10^8 CD3+ cells/kilogram)
Study: 23782711
Drug: Lenalidomide plus
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide plus low-dose dexamethasone (25 mg/day, adjusted for renal function)
Study: 23786513
Drug: Biological testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological testing for STI+
Study: 23787555
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (prednisone 1 mg/kg daily, max 60 mg/day) until complete remission, followed by gradual dosage reduction.
Study: 26917438
Drug: Mechanical debridement
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical debridement and systemic antibiotics
Study: 23790772
Drug: Neoadjuvant whole-pelvis
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant whole-pelvis radiation therapy (RT)
Study: 23791392
Drug: EMD 525797
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 525797 (250, 500, 1000, or 1500 mg every 2 weeks)
Study: 23791392
Drug: EMD 525797
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 525797 (500 mg cohort)
Study: 23791541
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m² on day 1 and bortezomib 1.3 mg/m² on days 1, 4, 8, 11 every 3 weeks
Study: 23794578
Drug: Weekly WelTel
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly WelTel SMS 'check-in'
Study: 23795577
Drug: LDMP 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDMP 7.5 mg (single dose on day 1)
Study: 23795577
Drug: LDMP 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDMP 7.5 mg (multiple doses, once daily for 14 days)
Study: 23795577
Drug: LDMP 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDMP 7.5 mg
Study: 23795661
Drug: peg-IFNα-2a 180
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peg-IFNα-2a 180 μg per week and ribavirin 1000/1200 mg daily for 48 weeks (Group A)
Study: 23795661
Drug: peg-IFNα-2a 180
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peg-IFNα-2a 180 μg per week and ribavirin 1000/1200 mg daily for 48 weeks (Group B)
Study: 23795661
Drug: peg-IFNα-2a 180
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peg-IFNα-2a 180 μg per week and ribavirin 1000/1200 mg daily for 24 weeks (Group C)
Study: 23795661
Drug: HCV RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV RNA below 1000 IU/mL by day 6
Study: 23796526
Drug: Behavioural modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural modification and risk factor treatment
Study: 23799873
Drug: Temsirolimus added
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus added to standard therapy of Rituximab and DHAP
Study: 23800144
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine treatment approach for chronic pain
Study: 23800355
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of one or more of 11 best practices for medication reconciliation
Study: 23800355
Drug: Baseline data
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline data collection on unintentional medication discrepancies
Study: 23801020
Drug: Implantable cardioverter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter defibrillator-only therapy
Study: 23803225
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg every 2 weeks) and low-dose interferon-α2a (3 MIU thrice weekly)
Study: 23805209
Drug: Concurrent partners
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent partners in the past year
Study: 23805395
Drug: Warm water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm water infusion colonoscopy
Study: 23809138
Drug: Intensive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid-lowering therapy with atorvastatin 40 mg and ezetimibe 10 mg